Catalyst Biosciences Inc (NASDAQ: CBIO)
Catalyst Biosciences is having a relatively strong day in the market today, and for good reason. The company released a PR early this morning that announced coming presentations. The presentations will surround the company’s candidates with hematology indications. Below, we’ll talk about the coming catalyst, what we’re seeing from CBIO today, and what investors should be watching for ahead.
The Coming Catalyst To Watch For With CBIO
As mentioned above, Catalyst Biosciences released a PR this morning, announcing that it will be giving presentations. The presentations will be held at the 10th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD). This event will be held on February 1st through 3rd in Paris France. In the PR, the company said that it would be providing two poster presentations at the conference.
Factor VIIa: The first presentation will be centered around Marzeptacog alfa (activated. This is a next-generation Factor VIIa. CBIO has already succesfully completed the Phase 1 clinical trial for the treatment designed to treat severe hemophilia A and B with and without inhibitors. The company intends on initiating the next study of marzeptacog alfa within the year 2017. This study will focus specifically on patients with hemophilia B with inhibitors. The poster presentation surrounding this treatment will be titled “PharmacokineticsAnd Pharmacodynamics Of Daily Subcutaneously Administered Marzeptacog Alfa (Activated) In Hemophilia Dogs, Levy et al.”
Factor IX: The second and third presentations surround CB 2679d/ISU304. This is a next-generation coagulation Factor IX variant. The treatment is currently in advanced pre-clinical development. Within the first quarter of 2017, CBIO intends on initiating a Phase ½ proof-of-concept study surrounding the treatment with regard to hemophilia B. The poster presentations with regard to CB 2679d/ISU304 are titled “Pharmacokinetics Of Subcutaneously Administered CB 2679d/ISU304 In Minipig Compared With Benefix, Hong et al.” and “Pharmacokinetics And Pharmacodynamics Of Daily Subcutaneous Administered CB 2679d/ISU304 In Hemophelia B Dogs, Levy et al.”
How The Market Reacted To The News
As investors, we know that the news moves the market. In this particular case Catalyst Biosciences released positive news. After all, biotech investors love to see progress on potential treatments, and that’s exactly what they’re expecting to see. As a result, CBIO is currently (12:48) trading at $0.59 per share after a gain of $0.02 per share or 2.77% thus far today.
What Investors Should Be Watching For Ahead
There’s no doubt in my mind that we’re going to see opportunity surrounding CBIO while these presentations are given. Investors should pay incredibly close attention to the news surrounding these presentations as they will give the community an idea of how strong the data surrounding both of these treatments are. Nonetheless, I’m expecting to see overwhelmingly positive news given recent data that has been provided by the company.
What Do You Think?
Where do you think CBIO is headed moving forward? Join the discussion in the comments below!